Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) plus platinum-based chemotherapy (PBC) vs placebo (PBO) plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

dc.contributor.authorBamias, A.
dc.contributor.authorDe Santis, M.
dc.contributor.authorArranz, J. A.
dc.contributor.authorGrande, E.
dc.contributor.authorGalsky, M. D.
dc.contributor.authorKikuchi, E.
dc.contributor.authorPark, S. H.
dc.date.accessioned2025-05-10T19:48:31Z
dc.date.issued2020
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionESMO Virtual Congress -- SEP 19-OCT 18, 2020 -- ELECTR NETWORK
dc.description.abstract[No abstract available]
dc.description.sponsorshipEuropean Soc Med Oncol
dc.description.sponsorshipF. Hoffmann-La Roche, Ltd.
dc.description.sponsorshipF. Hoffmann-La Roche, Ltd.
dc.identifier.doi10.1016/j.annonc.2020.08.770
dc.identifier.endpageS552
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.scopusqualityQ1
dc.identifier.startpageS551
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2020.08.770
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11729
dc.identifier.volume31
dc.identifier.wosWOS:000573469100693
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.titlePatient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) plus platinum-based chemotherapy (PBC) vs placebo (PBO) plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
dc.typeConference Object

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
11729.pdf
Boyut:
119.51 KB
Biçim:
Adobe Portable Document Format